BMS

Showing 15 posts of 286 posts found.

Working Life: BMS UK’s market access director Patrick Hopkinson

February 24, 2011
Business Services, Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Patrick Hopkinson, Working Life, recruitment

Patrick Hopkinson, director of market access and external affairs at Bristol-Myers Squibb UK, talks to Pharmafocus about how he got …

Blood clot fears halt cancer trial enrolment

February 3, 2011
Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer

Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …

NICE decides to back Abilify in schizophrenia

January 27, 2011
Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia

NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …

bristol-myers_squibb_dr_veronique_walsh

BMS appoints Dr Veronique Walsh

January 5, 2011
Sales and Marketing BMS, Bristol-Myers Squibb, Dr Véronique Walsh, appointment, sales and marketing

Bristol-Myers Squibb UK has appointed Dr Véronique Walsh as business unit director, neuroscience and immunoscience . She joins the company …

VTE trial boost for Pfizer and BMS’ apixaban

December 31, 2010
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism

Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …

BMS licences phase II HIV compound festinavir

December 22, 2010
Research and Development BMS, Bristol-Myers Squibb, HIV, NRTI, Oncolys BioPharma, festinavir, nucleoside reverse transcriptase inhibitor

Bristol-Myers Squibb is to pay hundreds of millions of dollars to a Japanese biotech firm to get its hands on …

Bristol-Myers Squibb appoints new UK general manager

December 13, 2010
Manufacturing and Production, Research and Development, Sales and Marketing Amadou Diarra, BMS, Bristol-Myers Squibb, appointment, recruitment, sales and marketing

Bristol-Myers Squibb has appointed Amadou Diarra as general manager of its UK company, where he will be in charge of …

NICE limits access to cancer drugs, study confirms

November 10, 2010
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta

NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests. The …

Advanced melanoma

BMS skin cancer drug hits US regulatory delay

November 3, 2010
Research and Development BMS, Bristol-Myers Squibb, FDA, MDX010-020 trial, ipilimumab, skin cancer

US regulators have announced they need more time to assess Bristol-Myers Squibb’s skin cancer treatment ipilimumab. The FDA will not …

BMS faces approval block unless GMP issues are resolved

November 2, 2010
Manufacturing and Production BMS, Bristol-Myers Squibb, FDA, Puerto Rico, belatacept, manufacturing compliance, pharma manufacturing

Bristol-Myers Squibb has been threatened with a block on approvals of certain new drugs, including a biologic for preventing organ …

Pharma manufacturing news in brief

October 26, 2010
Manufacturing and Production AMRI, BASF, BMS, Bend Research, Bristol-Myers Squibb, Parmetics, Stirling Pharma, Vical, pharma manufacturing

This week’s round-up of pharmaceutical manufacturing news features updates from Pharmetics, AMRI, Bend Research/BMS, Stirling Pharma, Vical and BASF. A …

Apixaban trial for ACS abandoned

October 20, 2010
Sales and Marketing ACS, BMS, Pfizer, apixaban

  Pfizer and Bristol-Myers Squibb have halted a trial of their heart drug apixaban after signs of increased risk of …

AZ-BMS diabetes drug impresses in phase III trials

October 1, 2010
Research and Development, Sales and Marketing AstraZeneca, BMS, dapagliflozin, diabetes

AstraZeneca and Bristol Myers Squibb’s potential first-in-class diabetes drug dapagliflozin has shown strong results in a late stage trial. It …

BMS poaches AZ’s head of global medical affairs

October 1, 2010
Research and Development, Sales and Marketing BMS, appointment, research and development, sales and marketing

Bristol-Myers Squibb has appointed Dr Rick Lones as executive medical director in the UK. He joins BMS from AstraZeneca, where …

FDA warns BMS over manufacturing plant in Puerto Rico

September 15, 2010
Manufacturing and Production BMS, FDA, GMP, Puerto Rico

A plant operated by Bristol-Myers Squibb in Puerto Rico has been cited by the US Food and Drug Administration for …

The Gateway to Local Adoption Series

Latest content